首页> 外文OA文献 >Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan

【2h】

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan

机译：评估欧尔替尼在先进的非小细胞肺癌中的评价：对美国健康保险计划预算的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Scott D. Ramsey; Lauren Clarke; Tripthi V. Kamath; Deborah Lubeck;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. [J] . Ramsey SD, Clarke L, Kamath TV, Journal of managed care pharmacy : . 2006,第6期

机译：高级非小细胞肺癌中尔特替尼的评价：对美国健康保险计划预算的影响。
2. Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer [J] . AokiT., IgawaS., FuruyaN., Anticancer Research: International Journal of Cancer Research and Treatment . 2012,第2期

机译：厄洛替尼治疗方案和启动时间对晚期非小细胞肺癌的影响
3. Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group [J] . Mountzios Giannis, Mavropoulou Xanthippi, Koliou Georgia-Angeliki, Anticancer Research: International Journal of Cancer Research and Treatment . 2020,第4期

机译：Bevacizumab对Erlotinib对先前未处理的晚期非小细胞肺癌患者肿瘤指标的影响：Hellenic合作肿瘤学群的研究
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to Non-Small Cell Lung Cancer. [D] . Mandal, Bivash. 2015

机译：针对非小细胞肺癌靶向药物递送的厄洛替尼负载杂化纳米颗粒的设计，开发和评估。
6. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis [O] . VF Fragoulakis, AG Pallis, DK Kaitelidou, 2012

机译：培美曲塞与厄洛替尼对希腊晚期/转移性非小细胞肺癌患者的二线治疗的经济评估：成本最小化分析
7. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan [O] . Jonathan Graham, Stephanie Earnshaw, Kate Burslem, 2018

机译：AFATINIB对一线转移性非小细胞肺癌患者的预算冲击分析，表皮生长因子受体外显子19缺失或外显子21替代突变在美国卫生计划中

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan

著录项

引文网络

相似文献

相关主题

期刊订阅